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ABSTRACT 
 
Purpose 
 
To study the incidence, risk factors and treatment for gross hemoglobinuria and oliguria 
following sclerotherapy for venous malformations. 
 
Materials and Methods 
 
The clinical records and imaging studies of patients with venous malformations who 
underwent sclerotherapy at our institution between July 1993 and August 2007 were 
reviewed. Demographic data, location and estimated size of the malformation, type and 
dose of the sclerosing agents, development of post-procedural hemoglobinuria and the 
treatment given were documented and analyzed. 
 
Results:  
 
475 procedures were performed on 131 patients with venous malformations (57 
males; 74 females, age range 2-58 years). The number of procedures ranged from 1 to 
21 (mean 3.6 procedures) per patient. 
Ethanol was used in 27 % of the procedures, sodium tetradecyl sulfate in 47 % and both 
agents in 26 %. 
Transient hemoglobinuria occurred after 34 % of sclerotherapy procedures and 57 % of 
these were associated with transient oliguria with increased risk with higher adjusted 
doses (sclerosant’s volume/ weight of patient) for both agents. Resolution of the 
hemoglobinuria and oliguria with hydration, alkalinization and diuretics was successful 
in all patients. The risk of hemoglobinuria increases with sclerotherapy of venous 
malformations affecting the lower extremities and multiple locations. 
 
Conclusions:  
 
Transient hemoglobinuria and oliguria are common complications of 
sclerotherapy for venous malformation. However, with proper fluid management, all the 
patients promptly recovered. The risk correlates with the volume of sclerosant (adjusted 
to patient’s weight) and is higher for lower extremity and multiple locations. 
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INTRODUCTION 
 
 
Venous malformations (VM) are developmental anomalies which can cause symptoms 
due to thrombosis, deformity and impairment of limb function. Treatment of venous 
malformations includes conservative measures (e.g. compression stockings), 
sclerotherapy, laser photocoagulation, anticoagulation and surgical resection. As many 
of these lesions are not surgically resectable, sclerotherapy has become the therapeutic 
mainstay [1]. Post-sclerotherapy hemoglobinuria is a known complication of 
sclerotherapy of venous malformation [2]. In this study, we evaluated the incidence, risk 
factors of developing this complication and treatment for this complication. 
 
 
MATERIALS AND METHODS 
 
 
This study was reviewed and approved by the Children’s Hospital Boston Committee 
on Clinical Investigation. A retrospective review of the medical records and imaging 
Studies was performed on all patients with venous malformations who underwent 
sclerotherapy in the Division of Interventional Radiology at Children's Hospital Boston 
from July 1993 through August 2007. Patients with combined vascular malformation or 
overgrowth syndromes with complex vascular anomalies were excluded from this study. 
The patients were initially evaluated by our multidisciplinary Vascular Anomalies 
Center or by an experienced interventionalist and the diagnosis of VM was established 
clinically and radiologically. 
For each procedure, demographic data, location and estimated size of the VM and type 
and dose of the sclerosant were documented. The locations of the VM included the 
cervicofacial, thoracic, pelviabdominal, upper extremity, lower extremity and multiple 
anatomical areas. Following sclerotherapy, the development of hemoglobinuria, oliguria 
and the treatment administered and outcome were also collected on all patients. For 
follow up, patients were contacted by telephone 1 day, 1 week, and 1 month after the 
procedure. 
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Assessment of the size of the venous malformation:  
 
The size of the lesion was divided into two major groups: measurable and non-
measurable based on the cross sectional 
imaging studies (MRI and CT). Non-measurable lesions were either very small 
(subcentimetric) or very large (involving a wide area and several tissue planes). 
 
Technique of Sclerotherapy 
 
The treatment was performed under general anesthesia using an established protocol [3]. 
Based on the discretion of the interventionalist, the sclerosing agent used was either 
98% ethanol, 3% sodium tetradecyl sulfate (STS) (Sotradecol, AngioDynamics, Inc. 
Queensbury, NY or Fibrovein, STD Pharmaceuticals, Hereford, UK) or both. Ethanol 
was opacified with oil-based contrast (Ethiodol, Savage Laboratories, Melville, NY) by 
mixing 10 ml of ethanol with 2 ml of Ethiodol. STS was made into foam by adding 
equal volume of air (or more) with or without Ethiodol. The dose of ethanol was limited 
to 1 ml/kg (not exceeding 60 ml) per procedure. The maximal dose of STS 3 % was 0.5 
mL/kg (not exceeding 30 ml) per procedure. 
 
Intra- operative and Post-operative Fluid Management 
 
Prior to sclerotherapy, a Foley catheter was inserted in the urinary bladder to monitor 
urine output and to observe for gross hemoglobinuria. The patients were generously 
hydrated throughout the procedure and recovery period. Intraoperatively, the 
preoperative fluid deficit was replaced with intravenous crystalloid (lactated Ringer’s) 
in the first 1-2 hours of the case, and fluids were then continued at 1 ½ - 2 times the 
maintenance rate. 
The color of the urine and the urine output were observed for the development of 
hemoglobinuria (pink to brown discoloration of urine) [Fig. 1]. If gross hemoglobinuria 
developed, the intravenous fluid was modified to D5W with 75 mEq/L sodium 
bicarbonate running at the maintenance rate to alkalinize the urine. Any additional fluid 
was administered as lactated Ringers or normal saline. During the recovery period, 
patients were kept on D5W with 75 mEq/L sodium bicarbonate running at 2 times 
maintenance until the urine was clear. Blood pH was not routinely checked. Oliguria 
(defined as urine output less than 1 ml/kg/hour) was treated with a bolus of IV normal 
saline (10-20 ml/kg) and a single small dose of intravenous furosemide (0.25 mg/kg). 
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Statistical analysis:  
 
Since gross hemoglobinuria is a binary outcome, we used a logistic 
regression model to analyze the relationship between the dose of agent (adjusted for 
weight) and the development of hemoglobinuria. Similarly, the effect of the anatomical 
locations of the malformation was studied. P value < 0.05 was considered statistically 
significant. 
 
 
RESULTS 
 
A total of 131 patients were included in the study with 57 males and 74 females. The 
age of the subjects ranged from 2 to 58 years (median 8 years). A total of 475 
procedures were performed with an average of 3.6 procedures per patient (range 1-21 
procedures). 
The following anatomical locations were treated: lower extremity (n=46, 35.1 %), head 
and neck (n=44, 33.6 %), upper extremity (n=18, 13.7 %), thorax (n=8, 6.1%), 
abdomenpelvis (n=8, 6.1 %) and multiple locations (n=7, 5.3 %). 57 patients had a 
measurable lesion and 62 patients had non-measurable lesions (very small in 16 and 
very large in 46) and data was not available on 12. 
Ethanol was used in 128 procedures (27%) of the procedures with a dose range of 3 to 
60 ml. 3% STS was used in 224 procedures (47%) with a dose range of 1-30 ml. A 
combination of both agents was used in 123 procedures (26%) with the same maximal 
doses. Post-sclerotherapy gross hemoglobinuria was noted towards the end of the 
procedure and/or during the recovery period in 162 procedures (34%). Ninety-two of 
these 162 procedures (57%) (or 19% of total number of procedures) were associated  
 
with transient oliguria. In all cases of oliguria, there was concomitant hemoglobinuria. 
The corrected dose (volume of agent/weight of patient) of both ethanol and STS 3% is a 
significant predictor of the development of hemoglobinuria. The odds of developing 
hemoglobinuria increased by 193 and 665 times for each volume/weight unit (ml/kg) 
increase for STS 3% and ethanol, respectively. 
As only a fraction of the subjects had measurable malformations, the statistical power to 
detect a difference was negatively affected. However, in our practice, the dose of 
sclerosant seems to correlates with the size of the venous malformation. Hence, after the 
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dose effect was included in the analysis, the effect of the size of the malformation was 
marginalized. For the anatomical location of the VM, only the lower extremity 
(P=0029) and multiple anatomical areas (P=0.0120) were associated with increase risk 
of hemoglobinuria. 
Treatment with adequate hydration, alkalinization of urine and diuretics was successful 
in all patients. 
 
DISCUSSION 
 
Venous malformations are the most common type of vascular anomalies. These 
malformations are present at birth, commonly symptomatic, grow proportionately with 
the patient and do not spontaneously regress (4). Since many VMs are not fully 
resectable and medical therapies are not predicted to have an effect in the absence of 
cellular proliferation or angiogenesis, sclerotherapy has emerged as the primary 
treatment option for venous malformations. Ideally, sclerotherapy of VMs is achieved 
with the controlled delivery of a toxic agent (sclerosant) which damages the endothelial 
lining of the malformation. The goal of this endothelial damage is the formation of 
irreversible occlusive thrombi to obliterate the slow-flow, dilated venous channels in 
these malformations. Recanalization after sclerotherapy or expansion of adjacent 
channels frequently requires repeated treatments, especially in larger malformations. 
The toxic effects of sclerosants at the biochemical and cellular level are significant. 
Buchta et al. reported tissue findings following infusion of ethanol into the renal artery 
in dogs (5). Electron microscopy showed that degeneration of the glomerular Basement 
membrane occurred in 2 minutes with necrosis of endothelial, epithelial, and mesangial 
cells and loss of nuclear structure. Detergent sclerosants (such as STS, sodium 
morrhuate, ethanolamine and polidocanol) produce endothelial damage, decreasing the 
endotelial cell surface tension, interfering with cell surface lipids, disrupting 
intercellular adhesión molecules, and extracting cell surface proteins (6). While not 
targeted by sclerotherapy, circulating erythrocytes are lysed, leading to significant 
release of free hemoglobina through at least two distinct mechanisms. First, direct 
membrane damage by sclerosants may lyse erythrocytes. Erythrocytes are significant 
components of venous thrombi, perhaps more so in slow-flow VMs, and prolonged 
exposure to sclerosant at the site of injury may enhance this mechanism of hemolysis. 
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Second, fibrin generation triggered by sclerotherapy may contribute to microangiopathic 
shearing of circulating erythrocytes. 
We have seen evidence of this on peripheral blood smears in some patients. 
Hemoglobin freed into the plasma is bound to haptoglobin (a protein produced by the 
liver). The halflife of haptoglobin-hemoglobin complexes is minutes, leading to rapid 
depletion of haptoglobin levels (7, 8). If haptoglobin is depleted by accelerated 
intravascular hemolysis, the resulting free hemoglobin is filtered by the kidneys and 
degraded by the renal tubular epithelium (9).  
 
Free plasma hemoglobin also depletes nitric oxide, which may consequently cause 
dystonias involving the gastrointestinal, cardiovascular, 
pulmonary and urogenital systems, as well as clotting disorders (10). 
The plasma ethanol level is directly proportional to the amount of ethanol injected and 
not dependent on the VM morphology, venous drainage, or injection technique (11). 
Nevertheless, none of our patients developed any clinically significant systemic 
hemolysis despite the fact that some of the received relatively large doses of two 
sclerosants. Despite some patients receiving relatively large doses of the two 
sclerosants, no patient developed complication of hemolysis beyond transient 
hemoglobinuria and oliguria. Gardner and Brooks studied the hematologic and 
coagulating parameters During endoscopic sclerotherapy of esophageal varices and 
found no evidence of disseminated intravascular coagulation (12). Despite some 
patients receiving relatively large doses of the two sclerosants, no patient in our study 
developed complication of hemolysis beyond transient hemoglobinuria and oliguria. 
It has been demonstrated that injection of sclerosants into the superior vena cava results 
in marked hemolysis and a significant decrease in creatinine clearance (13). Berenguer 
and colleagues reported gross hemoglobinuria in 28% of patients who underwent 
sclerotherapy for craniofacial venous malformations (2). The acute adverse effects of 
hemolysis on renal function following sclerotherapy were also common in our cohort. 
More than half of the patients with hemoglobinuria also developed oliguria. If evaluated 
with more sensitive measures - such as urine analysis for heme, circulating lactate 
dehydrogenase or haptoglobin levels – we would predict that the majority of patients 
have measurable hemolysis; though microscopic hemoglobinuria would not require 
intervention. 
Our study showed an increased probability of the development of hemoglobinuria 
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following sclerotherapy for VMs in the lower extremity and multiple locations. A 
plausible explanation for this result may be that lower extremity VMs tend to be large 
and require a larger volume of the sclerosants for effective sclerotherapy. 
 
Various measures have been advocated as prophylaxis against renal damage by free 
hemoglobin. Miyoshi and colleagues reported that haptoglobin prevents renal 
dysfunction associated with intravariceal infusion of ethanolamine oleate; a sclerosing 
agent similar to STS (14). Renal tubular function indices increased following 
sclerotherapy while glomerular filtration rate remained normal. Ohta et al. reported that 
albumin inhibits hemolysis induced by sclerotherapy for esophageal varices in a dose-
dependent manner (15). Our patients were typically healthy children with normal 
albumin, renal and liver function, and no interventions beyond hydration and 
alkalinization were necessary. None of them clinically developed any sequela of their 
transient hemoglobinuria and oliguria. 
We believe generous IV hydration is particularly crucial as patients have had a 
prolongad fast prior to the procedure and are likely to be dehydrated. While initiation of 
intravenous fluids prior to the start of the case would be ideal, it is not always possible 
in the pediatric population. Thus, it is our practice to quickly replace the preoperative 
deficit once intravenous access is obtained. We recommend the placement of a Foley 
catheter for observation of the color and volume of urine. Gross hematuria developed 
during or immediately following the procedure, and patients were not discharged home 
until they had fully recovered from general anesthesia and had resumed the production 
of clear urine. 
This study is not without limitations: the retrospective nature, the heterogenous size and 
location of the VMs, the variable doses and combinations used and lack of information 
about the systemic levels of the sclerosants made it difficult to quantify the effect of 
sclerosants on the erythrocytes and the subsequent biochemical and clinical sequelae. 
In conclusion, our study demonstrated that gross hemoglobinuria and oliguria are 
common, transient sequelae of sclerotherapy for venous malformations using ethanol 
and sodium tetradecyl sulfate. The lower extremity and multiregional venous 
malformation are more likely to develop this complication. The higher dose (ml/kg) of 
the sclerosants is a strong predictor of these complications and treatment with hydration 
and diuresis is effective. 
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CAPTIONS 
 
 
Figure 1. Early development of hemoglobinuria during sclerotherapy for VM. Note the 
faint reddish-brownish discoloration of the urine which occurred after the injection of 
the sclerosant, compared to the clear urine obtained earlier. 
 
 
